September 19, 2011
The new drug application (NDA) review report issued on the cervical cancer vaccine Gardasil (human papillomavirus quadrivalent vaccine, recombinant), approved on July 1, has revealed that a number of problems were found in clinical trials conducted in Japan and abroad...read more